â– LECTURE OVERVIEW: Delirium Tremens (DTs) is the most severe and life-threatening manifestation of the alcohol withdrawal syndrome.
â– HYPEREXCITABLE NEURAL MECHANISMS:
1. Chronic GABA Drive: Chronic alcohol use continuously stimulates inhibitory GABA-A receptors, prompting down-regulation of these receptors, and continually blocks excitatory NMDA glutamate receptors, prompting up-regulation of NMDA receptors.
2. Abrupt Cessation: When alcohol is abruptly discontinued, the sudden loss of inhibitory GABA stimulation paired with an unregulated glutamatergic drive causes severe, systemic central nervous system hyperexcitability.
3. Autonomic Storm: Drives a severe sympathetic storm, characterized by extreme hypertension, hyperthermia, tachycardic arrhythmias, and psychomotor agitation.
â– THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
â– CLINICAL REGISTRY INSIGHTS:
Patient registry reviews depict high clinical validity in diverse populations, indicating highly correlated trends of symptom development and treatment responsiveness.
[HY-BOARD-1004]
🌟 Dynamic Clinical Key:
DTs typically begins 48-96 hours after the last drink, presenting with altered sensorium, disorientation, and vivid visual/tactile hallucinations (e.g., crawling insects). First-line treatment is aggressive intravenous Benzodiazepines (e.g., Diazepam, Lorazepam) to restore GABAergic inhibition and prevent status epilepticus. Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Assess demographic representation when applying trial results to real-world patients.